Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant

Senores Pharmaceuticals to increase stake in Havix to 54.96%

Havix was incorporated under the laws of the State of Delaware on February 17, 2015

Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy’s Laboratories

The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA

Senores Pharmaceuticals begins operations at greenfield API facility

This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.

Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets

Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25

PAT after MI is Rs. 41 crore which is 162% increase

Senores receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure

Senores Pharmaceuticals IPO lists at 53% premium

The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline

Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories

The product will be marketed by Dr. Reddy's

Senores Pharmaceuticals gets SEBI nod for IPO

The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements